Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription 20.07.2026 1 Am J Gastroenterol 1 Biochem Biophys Res Commun 2 BMC Cancer 11 BMC Gastroenterol 1 Cancer Res 1 Dig Dis 3 Dig Dis Sci 1 Endoscopy 1 Gastroenterology 1 Gastrointest Endosc 11 Hepatology 3 J Clin Oncol 1 J Comput Assist Tomogr 4 J Gastroenterol Hepatol 11 J Hepatol 1 J Pediatr Surg 1 PLoS Comput Biol 4 PLoS One 1 Proc Natl Acad Sci U S A 2 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. BAJAJ JS, Heuman DM
   How I manage cirrhosis in a busy outpatient clinic? The P.O.R.T.A.L.V.E.I.N. mnemonic.
   Am J Gastroenterol. 2026 Jul 10. doi: 10.14309/ajg.0000000000004118.
   PubMed        
   
   

   
   Biochem Biophys Res Commun

2. WANG Y, Wang Y, Yuan J, Dong S, et al
   Integrated multi-omics identification and experimental validation of ACSL4-associated ferroptotic lipid remodeling in drug-induced acute liver failure.
   Biochem Biophys Res Commun. 2026;829:153960.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. LAN HM, Chen L, Yang S, Huang LS, et al
   NLR-based nomogram predicts survival in hepatocellular carcinoma treated with TACE plus targeted immunotherapy.
   BMC Cancer. 2026 Jul 13. doi: 10.1186/s12885-026-16436.
   PubMed         Abstract available
   
   
4. LI S, Yu G, Wang S, Wang M, et al
   Effectiveness and safety of PD-1/PD-L1 inhibitors plus lenvatinib with or without Gemox chemotherapy in advanced intrahepatic cholangiocarcinoma.
   BMC Cancer. 2026 Jul 16. doi: 10.1186/s12885-026-16392.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

5. LUO C, Xu H, Huang T, Fan R, et al
   Impact of lymph node dissection on textbook outcomes in patients with intrahepatic cholangiocarcinoma: a multi-center analysis.
   BMC Gastroenterol. 2026 Jul 10. doi: 10.1186/s12876-026-05090.
   PubMed         Abstract available
   
   
6. SHAABAN ABDELGALIL M, Abdelrazek A, Mohamed MS, Hassan A, et al
   EUS-guided hepaticogastrostomy versus EUS-guided hepaticogastrostomy with antegrade stent placement in patients with unresectable malignant distal biliary obstruction: a meta-analysis of individual patient data.
   BMC Gastroenterol. 2026;26:440.
   PubMed         Abstract available
   
   
7. JALLAD H, Khaled A, Qabaja H, Qabaja YA, et al
   Masked polycythemia vera presenting as non-cirrhotic portal hypertension with isolated gastric varices: a case report.
   BMC Gastroenterol. 2026 Jul 13. doi: 10.1186/s12876-026-05111.
   PubMed         Abstract available
   
   
8. REN L, Suwanbai M, Shi L, Yan S, et al
   Early antibiotic exposure reduces progression-free survival in unresectable hepatocellular carcinoma patients treated with TACE plus TKI and ICI therapy: a propensity score-matched analysis.
   BMC Gastroenterol. 2026 Jul 15. doi: 10.1186/s12876-026-05126.
   PubMed         Abstract available
   
   
9. CHEN S, Shi Y, Pang Y, Wang X, et al
   Hepatic and splenic tuberculosis following infliximab therapy for refractory ulcerative colitis: a case report and literature review.
   BMC Gastroenterol. 2026 Jul 16. doi: 10.1186/s12876-026-05116.
   PubMed         Abstract available
   
   
10. WANG X, Shen J, Guo J, Dong X, et al
    Inflammatory mediators are predictors of clinical outcomes in cirrhotic patients with non-acute decompensation.
    BMC Gastroenterol. 2026 Jul 17. doi: 10.1186/s12876-026-05105.
    PubMed         Abstract available
    
    
11. LI D, Liao Y, Yao S, Li H, et al
    FBXW8 is upregulated in hepatocellular carcinoma and promotes HCC cell malignancy.
    BMC Gastroenterol. 2026 Jul 17. doi: 10.1186/s12876-026-05146.
    PubMed         Abstract available
    
    
12. BETIKU O, Ojumu T, Oladele J, Olaofe O, et al
    Desmoid fibromatosis of the liver: a case report and rare entity with diagnostic resolution by histopathology and immunohistochemistry.
    BMC Gastroenterol. 2026;26:430.
    PubMed         Abstract available
    
    
13. QIN Z, Yang K, Liang Z, Gao L, et al
    Association of metabolic vulnerability index with various chronic liver diseases and mortality: a large prospective cohort study.
    BMC Gastroenterol. 2026;26:452.
    PubMed         Abstract available
    
    
14. MOUSA N, Elmetwalli A, Abdelsalam M, Wahba M, et al
    Albumin-to-creatinine ratio as non-invasive marker for prediction of non- bleeding esophageal varices. a cross-sectional observational study.
    BMC Gastroenterol. 2026;26:439.
    PubMed         Abstract available
    
    
15. KRATZER W, Binzberger A, Kauschke SG, Dolze F, et al
    Point shear wave elastography for non-invasive detection of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: a prospective histologically validated study.
    BMC Gastroenterol. 2026;26:451.
    PubMed         Abstract available
    
    

    
    Cancer Res

16. XU S, Huang JY, Wang K, Xiang YJ, et al
    ARID1A Stimulates Notch-TLL1 Signaling to Induce Cancer-Associated Fibroblast Activation and Intrahepatic Cholangiocarcinoma Development.
    Cancer Res. 2026 Jul 17. doi: 10.1158/0008-5472.CAN-25-5082.
    PubMed         Abstract available
    
    

    
    Dig Dis

17. CHIU YC, Tsai HJ, Chen CC, Lin YC, et al
    Predictors of Incident High-Risk Varices in Patients with Hepatitis B-related Cirrhosis Receiving Nucleos(t)ide Analogue Therapy.
    Dig Dis. 2026 Jul 16:1-20. doi: 10.1159/000553519.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

18. LUOGU A, Qian S, Tai Y, Wei B, et al
    Interventional Therapy for Hepatic Hydatidosis with Cavernous Transformation of Portal Vein.
    Dig Dis Sci. 2026 Jul 13. doi: 10.1007/s10620-026-10116.
    PubMed         Abstract available
    
    
19. DUAN J, Jiang R, Yuan L, Xu X, et al
    A Prognostic Model Based on Adipokine-Related Genes for Hepatocellular Carcinoma: Assessment of Patient Outcomes and Tumor Microenvironment Characterization.
    Dig Dis Sci. 2026 Jul 17. doi: 10.1007/s10620-026-10122.
    PubMed         Abstract available
    
    
20. DANPANICHKUL P, Duangsonk K, Faulkner CS, Sirimangklanurak S, et al
    Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease.
    Dig Dis Sci. 2026;71:2165-2173.
    PubMed         Abstract available
    
    

    
    Endoscopy

21. OKAMOTO K, Uza N, Tsujimae M, Sakai A, et al
    Successful retrieval of a misdeployed stent using a drill dilator during endoscopic ultrasound-guided hepaticogastrostomy: a useful technique with a potential pitfall.
    Endoscopy. 2026 Jul 13. doi: 10.1055/a-2904-0208.
    PubMed        
    
    

    
    Gastroenterology

22. EL-DEBEIKY S, Hiu-Fung Lam T, Sze-Man Lai M, Tse YK, et al
    Long-term incidence of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Gastroenterology. 2026 Jul 13:S0016-5085(26)07043.
    PubMed         Abstract available
    
    

    
    Gastrointest Endosc

23. SAMARASENA J
    Endoscopic ultrasound-guided transjugular intrahepatic portosystemic shunt? Not exactly.
    Gastrointest Endosc. 2026;104:298-299.
    PubMed        
    
    

    
    Hepatology

24. XIAO-YONG H, Ai-Wu K, Guo-Ming S, Xin Z, et al
    Erratum: AlphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.
    Hepatology. 2026;84:E48-E49.
    PubMed        
    
    
25. KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
    Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
    Hepatology. 2026;84:E50.
    PubMed        
    
    
26. PREMKUMAR M, Sandhu A, Sharma P, Nain J, et al
    Recompensation of decompensated cirrhosis in a spectrum of metabolic-dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors.
    Hepatology. 2026 Jul 17. doi: 10.1097/HEP.0000000000001822.
    PubMed         Abstract available
    
    
27. KROWKA MJ, DuBrock HM, Raevens S, Fallon MB, et al
    Unmet needs in diagnosis and management of portopulmonary hypertension: How far have we reached?
    Hepatology. 2026;84:573-581.
    PubMed         Abstract available
    
    
28. LEE PC, Wu CJ, Hung YW, Lee CJ, et al
    Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy.
    Hepatology. 2026;84:411-423.
    PubMed         Abstract available
    
    
29. LIU Y, Wang X, Krishnan N, Hsiao T, et al
    Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles.
    Hepatology. 2026;84:424-439.
    PubMed         Abstract available
    
    
30. SHI Y, Zhou R, Kim SU, Yip TC, et al
    Association between longitudinal weight change and clinical outcome in individuals with MASLD.
    Hepatology. 2026;84:514-528.
    PubMed         Abstract available
    
    
31. ZHOU XD, Chen QF, Fan QY, Kim SU, et al
    Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD.
    Hepatology. 2026;84:529-541.
    PubMed         Abstract available
    
    
32. ZHOU SQ, Wang LN, Wu LF, Sun LY, et al
    Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.
    Hepatology. 2026;84:453-468.
    PubMed         Abstract available
    
    
33. SCHRADER C, Fromme M, Ellis P, Payance A, et al
    Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency.
    Hepatology. 2026;84:542-558.
    PubMed         Abstract available
    
    
34. HERNANDEZ-GEA V, Paradis V, Guindi M, Alves VAF, et al
    A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.
    Hepatology. 2026;84:601-616.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

35. JIN ZC, Zhong BY, Zhu HD, Teng GJ, et al
    Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing?
    J Clin Oncol. 2026 Jul 10:JCO2601336. doi: 10.1200/JCO-26-01336.
    PubMed        
    
    
36. AKKUS E
    Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing?
    J Clin Oncol. 2026 Jul 10:JCO2600529. doi: 10.1200/JCO-26-00529.
    PubMed        
    
    
37. CHAN LL, Chan SL
    Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing?
    J Clin Oncol. 2026 Jul 10:JCO2601342. doi: 10.1200/JCO-26-01342.
    PubMed        
    
    

    
    J Comput Assist Tomogr

38. ZAREI M, Ria F, Jensen CT, Liu X, et al
    Correlation of Automated in Vivo Image Quality With Radiologist's Performance in Abdomen Computed Tomography Across Conventional and Deep Learning Reconstructions.
    J Comput Assist Tomogr. 2026;50:656-661.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

39. KUMAR S, Shaikh MM
    Methodological Considerations in Interpreting IL-15 Plus Thymosin alpha1 Therapy for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2026 Jul 17. doi: 10.1111/jgh.70607.
    PubMed        
    
    
40. ULLAH W, Ashok K, Jawad M, Antar AS, et al
    Comments on IL-15 Plus Thymosin alpha1 Reduces Senescent Hepatic CD8+ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
    J Gastroenterol Hepatol. 2026 Jul 16. doi: 10.1111/jgh.70592.
    PubMed        
    
    
41. STIRRAT T, Hu B, Flatley M, Apte S, et al
    Gender Authorship in Gastroenterology and Hepatology: Trends and Persistent Seniority Gaps.
    J Gastroenterol Hepatol. 2026 Jul 14. doi: 10.1111/jgh.70552.
    PubMed         Abstract available
    
    
42. LIN SH, Wu JL, Tsai YN, Tseng CH, et al
    Comparative Effectiveness and Safety of Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab as First-Line Systemic Therapy for Hepatocellular Carcinoma: A Real-World Study.
    J Gastroenterol Hepatol. 2026 Jul 10. doi: 10.1111/jgh.70555.
    PubMed         Abstract available
    
    

    
    J Hepatol

43. SHEN SJ, Zhou K, Wang CY, Li H, et al
    Setdb1 represses anti-tumor immunity and tertiary lymphoid structures in hepatocellular carcinoma.
    J Hepatol. 2026 Jul 16:S0168-8278(26)02715-7. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
44. INCICCO S, Patidar KR, Juanola A, Ma AT, et al
    Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis.
    J Hepatol. 2026 Jul 15:S0168-8278(26)02717-0. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
45. KRAMER G, Hildeman A, Tozzi C, Maghsood R, et al
    A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: the CIRI model.
    J Hepatol. 2026 Jul 16:S0168-8278(26)02716-9. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
46. CHEN Q, Yang W, Yuan YZ, Cai FZ, et al
    Disruption of carbon metabolism by the hepatic mononuclear phagocytic system drives liver injury in a mouse model of severe dengue.
    J Hepatol. 2026 Jul 16:S0168-8278(26)02737-6. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
47. CAMPANI C, Laurent-Puig P, Villeret F, Benmerabet Y, et al
    Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative.
    J Hepatol. 2026;85:289-300.
    PubMed         Abstract available
    
    
48. SCHATTENBERG JM, Bedossa P, Guy CD, Taub R, et al
    Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial.
    J Hepatol. 2026;85:202-211.
    PubMed         Abstract available
    
    
49. MANCO R, Moliterni C, Neirynck G, Claus R, et al
    Liver Sinusoidal Endothelial Cells and Laminin dictate cholangiocytes' fate in chronic liver disease.
    J Hepatol. 2026 Mar 27:S0168-8278(26)00148-0. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
50. BRAADLAND PR, Ali AH, Puchas P, Juran BD, et al
    Vitamin B6 predicts poor outcomes in geographically distinct populations with primary sclerosing cholangitis.
    J Hepatol. 2026 Apr 17:S0168-8278(26)00203-5. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
51. HARLOW C, Mohamad M, Bajaj JS, Nibali L, et al
    Harnessing the oral microbiome in chronic liver disease: Mechanisms, therapeutic modulation and translational frontiers.
    J Hepatol. 2026;85:395-412.
    PubMed         Abstract available
    
    
52. GALLAGE S, Castro RE, Estall J, Tabas I, et al
    EASL position paper on preclinical models of steatotic liver disease.
    J Hepatol. 2026;85:345-382.
    PubMed         Abstract available
    
    
53. HERNANDEZ-GEA V, Paradis V, Guindi M, Alves VAF, et al
    A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.
    J Hepatol. 2026;85:383-394.
    PubMed         Abstract available
    
    

    
    J Pediatr Surg

54. FUCHS J, Rabaux-Eygasier L, Hery G, Fouquet V, et al
    Textbook Outcome After Hepatoblastoma Resection: Definition, Failure Modes, and Risk-Adjusted Benchmarking in a Tertiary European Center.
    J Pediatr Surg. 2026 Jul 16:163308. doi: 10.1016/j.jpedsurg.2026.163308.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

55. LIU Y, Hu K, Geng J, Dai Q, et al
    Integrating multi-type features and knowledge graph for graded prediction of drug-induced liver injury in humans.
    PLoS Comput Biol. 2026;22:e1013640.
    PubMed         Abstract available
    
    

    
    PLoS One

56. YUEN MF, Wastlund D, Lin TTY, Zheng Q, et al
    Surveillance of hepatocellular carcinoma (HCC) patients using Protein Induced by Vitamin K (PIVKA-II): A cost-utility analysis for Hong Kong.
    PLoS One. 2026;21:e0353882.
    PubMed         Abstract available
    
    
57. MENG X, Li Y, He M, Wang C, et al
    Sodium butyrate induces mitochondrial pathway apoptosis in liver cancer via ATF4/SLC7A11-mediated ferroptosis.
    PLoS One. 2026;21:e0353653.
    PubMed         Abstract available
    
    
58. FRISCH A, Kahn J, Collettini F, Steinhagen P, et al
    Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy.
    PLoS One. 2026;21:e0352018.
    PubMed         Abstract available
    
    
59. AL-TAMEEMI NK, Grove JI, Hoad CL, Wai JWS, et al
    The impact of pectin supplementation on systemic inflammation pathways, gut microbiome, and metabolic health in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A study protocol for a randomised controlled trial.
    PLoS One. 2026;21:e0352397.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

60. ZHANG S, Wang H, Cho Y, Rocha HL, et al
    Quantitative calibration of a spatial QSP model identifies fibroblast impact on HCC immunotherapy.
    Proc Natl Acad Sci U S A. 2026;123:e2525799123.
    PubMed         Abstract available
    
    

    
    Radiology

61. PARAMESWARAN M, Baikpour M, Hunt DT, Orlowski M, et al
    Best Practice: Implementation of Liver US Shear-Wave Elastography in Clinical Practice.
    Radiology. 2026;320:e252544.
    PubMed         Abstract available
    
    
62. LEE L, Lee J, Hao F, Lee EW, et al
    Robotic-assisted (90)Y Transarterial Radioembolization for Treatment of Hepatocellular Carcinoma: Initial Experience.
    Radiology. 2026;320:e253870.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum